MICHAEL GRAVES - Corporate Board Profile

EAGLE PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2015-06-25	Michael Graves has served as a member of our Board since November 2013. In January 2012 Mr. Graves joined the Board of Directors of RiboCor, Inc. and in December 2013, Mr. Graves was appointed chairman of the Board of Directors of Nanocopoeia, Inc., both private pharmaceutical companies. From May 2007 to July 2011, Mr. Graves served as the chief executive officer and president of Paddock Laboratories, Inc., a pharmaceutical company engaged in the manufacture, distribution and marketing of bioequivalent generic pharmaceuticals. From September 2005 to November 2006, Mr. Graves served as president of the generic products division at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals. While at Par, Mr. Graves oversaw the strategy development of Par's generic pharmaceutical business. Beginning in 1998, Mr. Graves served as director of marketing and sales operations of Par, and in 2004, Mr. Graves was promoted to senior vice president of corporate development and strategic planning. Mr. Graves served in this position until his promotion to president of the generic products division in September 2005. Mr. Graves holds a B.S. from State University College of New York at Buffalo. Our Board believes that Mr. Graves' extensive experience in marketing, sales, business development and operations qualifies him to serve on our Board.
2016-07-12	The following table sets forth in summary form information concerning the compensation that we paid or awarded during the fiscal year ended December 31, 2015, and during the three-month transition period ended December 31, 2014, to each of our non-employee directors: Michael Graves 2015 51,500 250,719 302,219
2017-04-28	Michael Graves has served as a member of our Board since November 2013. In June 2016, our Board appointed Mr. Graves chairman of the Board. In January 2012 Mr. Graves joined the board of directors of RiboCor, Inc. and in December 2011, Mr. Graves was appointed chairman of the board of directors of Nanocopoeia, Inc., both private pharmaceutical companies. From May 2007 to July 2011, Mr. Graves served as the chief executive officer and president of Paddock Laboratories, Inc., a pharmaceutical company engaged in the manufacture, distribution and marketing of bioequivalent generic pharmaceuticals. From September 2005 to November 2006, Mr. Graves served as president of the generic products division at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals. While at Par, Mr. Graves oversaw the strategy development of Par's generic pharmaceutical business. Beginning in 1998, Mr. Graves served as director of marketing and sales operations of Par, and in 2004, Mr. Graves was promoted to senior vice president of corporate development and strategic planning. Mr. Graves served in this position until his promotion to president of the generic products division in September 2005. Mr. Graves holds a B.S. from State University College of New York at Buffalo. Our Board believes that Mr. Graves' extensive experience in marketing, sales, business development and operations qualifies him to serve on our Board.
2018-04-30	Michael Graves has served as a member of our Board since November 2013. In June 2016, our Board appointed Mr. Graves chairman of the Board. ... Our Board has established an audit committee, a compensation committee, and a nominating and corporate governance committee... Audit Committee: Steven Ratoff (Chair), Michael Graves, Robert Glenning; Compensation Committee: Michael Graves (Chair), Sander Flaum, Douglas Braunstein. 2017 Director Compensation Table: Michael Graves 2017 Fees Earned or Paid in Cash $137,500, Option Awards $320,045, Total $457,545.
2019-04-30	Michael Graves has served as a member of our Board since November 2013 and as chairman since June 2016. He has extensive experience in marketing, sales, business development and operations. 2018 director compensation table shows $392,278 total compensation.
2021-04-30	Michael Graves(1)(2)(3) I 58 Chairman of the Board 2013 2021 2024 (1) Member of our audit committee. (2) Member of our compensation committee. (3) Member of our nominating and corporate governance committee. 2020 Director Compensation Table Michael Graves 2020 170,000 302,681 472,681 The following table sets forth in summary form information regarding the compensation earned for service on our Board during the year ended December 31, 2020 by our directors who were not also our employees.
2022-06-15	Michael Graves has served as a member of our Board since November 2013 and as chairman of the Board since June 2016. He is chair of our compensation committee and a member of our audit committee and nominating and corporate governance committee. His 2021 total compensation was $490,761 as shown in the Director Compensation Table.
2023-05-01	Michael Graves (1)(3) Member of our audit committee, which is chaired by Steven Ratoff. Member of our nominating and corporate governance committee, which is chaired by Michael Graves. Michael Graves served as chair of our compensation committee until November 2022, when he stepped down as chair and as a member of the compensation committee and was replaced by Robert Glenning as chair of the compensation committee.